NCT00179699View on ClinicalTrials.gov

Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2005

Study Completion Date

November 30, 2006

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

CC-5013

DRUG

pemetrexed

Trial Locations (5)

32806

MD Anderson - Orlando, Orlando

40202

Norton Healthcare, Louisville

52242

University of Iowa, Iowa City

63110

Washington University, St Louis

11733-3456

North Shore Hem/Onc Associates, East Setauket

Sponsors
All Listed Sponsors
collaborator

Prologue Research International

INDUSTRY

lead

Celgene Corporation

INDUSTRY